Effect of Pirfenidone on Risk of Pulmonary Fibrosis in COVID-19 Patients Experiencing Cytokine Storm.
Marian S BoshraAhmed E Abou WardaMahmoud Abdulbasser SayedMohammed H ElkomyNasser H AlotaibiMarwa MohsenRania M SarhanPublished in: Healthcare (Basel, Switzerland) (2022)
= 0.006 and 0.01, respectively). Our findings show that Pirfenidone inhibits fibrosis advancement in COVID-19 patients with pulmonary fibrosis and is associated with hepatotoxicity and GI distress. It may be beneficial in patients with mild to moderate COVID-19-induced pulmonary fibrosis; however, additional research is necessary.